Needham Reiterates Hold on Amphastar Pharma
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Hold rating on Amphastar Pharmaceuticals (NASDAQ:AMPH), indicating no change in the investment firm's stance towards the company's stock.
April 10, 2024 | 11:24 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Serge Belanger reiterated a Hold rating on Amphastar Pharmaceuticals, suggesting no immediate positive or negative changes in the company's outlook.
The reiteration of a Hold rating by a significant analyst suggests that there are no immediate catalysts expected to significantly change the stock's performance in the short term. This analysis is based on the information provided by the analyst and does not indicate a strong movement in either direction.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 90